Celgene
CompanyUnited States
Celgene develops one asset, in phase 2 (BMS-986368 in agitation). Mostly small molecule acting on lipid and ceramide metabolism, inflammation and FAAH; based in the United States.
- Assets
- 1
- Furthest
- Phase 2
- Trials
- 56
- Signals
- 1
Pipeline
1Dual FAAH and MAGL inhibitor elevating endocannabinoid levels to reduce spasticity
Phase 2Small moleculeLipid and ceramide metabolismInflammationagitationAlzheimer's disease
Full company profiles: pipeline, trials, funding and people.
See Pro- Evidence behind the mechanisms3
- Trials173
- Signals2
- Similar companies6
Updated 7 Oct 2026 · 175 sources